Rasmussen, A
Fuchs, J
Hansen, L H
Larsen, M
Sander, B
Lund-Andersen, H
Article History
First Online: 20 January 2017
Competing interests
: AR received travel support from Novartis. JF received travel support from Novartis. LHH is an advisory board member for Bayer and received travel support and lecture fees from Novartis. ML is an advisory board member for Novartis, Pfizer, Thrombogenics and received lecture fees from Novartis, Pfizer, Novo Nordisk and GlaxoSmithKline. The remaining authors declare no conflict of interest.